US HBW Executive Decisions: Bausch + Lomb CMO, GOED Expands Staff
Executive Summary
Yehia Hashad joins Bausch + Lomb as R&D executive VP and chief medical officer before a planned IPO; Global Organization for EPA and DHA Omega-3s begins 2022 creating a position of growth and engagement director and adding two team members.
You may also be interested in...
HBW News: CRN Expands Staff, Sami-Sabinsa CEO Dies, GOED Database Study Published
Sami-Sabinsa announces death of CEO Nair; government affairs director, scientific/regulatory affairs manager, membership associate join CRN; and GOED launches database with more than 45,000 EPA, DHA studies.
US Q1 Consumer Health Earnings Preview: Pivoting From Planning Changes To Parsing Results
Inflation's impact on consumer spending will be front and center in sector’s quarterly reports, beginning with J&J on 19 April. Potential impact also from price hikes common from most firms since early 2021 in response to increasing costs. Russia’s invasion of Ukraine also will prompt comment.
In Flip Of Bausch Health’s Planned Order For IPOs, Bausch + Lomb Registration Comes Before Solta
“We are positioned to move forward with either the Bausch + Lomb or Solta IPO quickly when market conditions are right for each of them,” CEO Joseph Papa says at J.P. Morgan conference, but the firm’s “next step” in the process of separating the two businesses was filing with the SEC an IPO registration for Bausch + Lomb.